Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

GlobeNewswire

1 hour ago

BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2664856297"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664856297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664856297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664856297","market":"hk","top_or_hot":-1,"title":"Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference","media":"GlobeNewswire","content":"<html><body><p>BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p>The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> <p><strong>ABOUT LEGEND BIOTECH</strong></p> <p>With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>®</sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</p> <p>Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.</p> <p><strong>INVESTOR CONTACT:</strong><br/>Caroline Paul<br/>Tel: (973) 650-5832<br/>Caroline.Paul@legendbiotech.com</p> <p><strong>PRESS CONTACT:</strong><br/>Kim Fox<br/>Tel: (848) 388-8445<br/><u>media@legendbiotech.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZTg0ZjkxMTItYTMzNS00MGZjLTgxYzEtMTlkNzgzZmU1MjI4LTEyMDY1MDUtMjAyNi0wOS0wMS1lbg==/tiny/Legend-Biotech-USA-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech to Participate in the Morgan Stanley Global Healthcare Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-09-01 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET.</p> <p>The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast.</p> <p><strong>ABOUT LEGEND BIOTECH</strong></p> <p>With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>®</sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</p> <p>Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn.</p> <p><strong>INVESTOR CONTACT:</strong><br/>Caroline Paul<br/>Tel: (973) 650-5832<br/>Caroline.Paul@legendbiotech.com</p> <p><strong>PRESS CONTACT:</strong><br/>Kim Fox<br/>Tel: (848) 388-8445<br/><u>media@legendbiotech.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/ZTg0ZjkxMTItYTMzNS00MGZjLTgxYzEtMTlkNzgzZmU1MjI4LTEyMDY1MDUtMjAyNi0wOS0wMS1lbg==/tiny/Legend-Biotech-USA-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354079/0/en/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference.html","article_id":"2664856297","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664856297","pubTimestamp":1788264000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","FBT":"First Trust NYSE Arca Biotechnology Index Fund","BK4505":"高瓴资本持仓","XBI":"SPDR S&P Biotech ETF","CNCR":"Range Cancer Therapeutics ETF","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","IBB":"生物科技指数ETF-iShares Nasdaq","MEDI":"HARBOR HEALTH CARE ETF","BK4588":"碎股","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","HCSG":"Healthcare Svcs Group Inc","IBBQ":"Invesco Nasdaq Biotechnology ETF","SYNB":"PUTNAM BIOREVOLUTION ETF","CANC":"TEMA ONCOLOGY ETF","BK4137":"综合支持服务","XLV":"健康照护类股ETF-SPDR","LEGN":"传奇生物","BK4581":"高盛持仓","GNOM":"Global X Genomics & Biotechnology ETF","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念"},"translate_title":"传奇生物将参加摩根士丹利全球医疗保健大会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNCR":0.75,"FBT":0.75,"MEMS":0.6,"XBI":1.5,"XLV":1.5,"TBXU":0.75,"LEGN":1.5,"MEDI":0.6,"HCSG":1.5,"LFSC":0.75,"CANC":0.6,"SYNB":0.75,"IBB":0.75,"LABU":0.6,"IBBQ":0.75,"GNOM":0.75},"content_text":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities. Learn more at www.legendbiotech.com and follow us on X, Instagram, and LinkedIn. INVESTOR CONTACT:Caroline PaulTel: (973) 650-5832Caroline.Paul@legendbiotech.com PRESS CONTACT:Kim FoxTel: (848) 388-8445media@legendbiotech.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}